Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis.

Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, Hige S, Sakamoto M, Kage M, Mizokami M, Narimatsu H.

Sci Rep. 2013;3:1065. doi: 10.1038/srep01065. Epub 2013 Jan 15.

2.

Hepatic fibrosis in patients with chronic hepatitis C assessed by transient elastography: implications for determining the efficacy of antiviral therapy.

Mendoza J, Trapero-Marugán M, González-Moreno L, Jones EA, Gómez-Domínguez E, Moreno-Otero R.

Rev Esp Enferm Dig. 2010 Jul;102(7):426-34.

3.

Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C.

Koretz RL, Pleguezuelo M, Arvaniti V, Barrera Baena P, Ciria R, Gurusamy KS, Davidson BR, Burroughs AK.

Cochrane Database Syst Rev. 2013 Jan 31;1:CD003617. doi: 10.1002/14651858.CD003617.pub2. Review.

PMID:
23440791
4.
5.

Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin.

Valenti L, Aghemo A, Stättermayer AF, Maggioni P, De Nicola S, Motta BM, Rumi MG, Dongiovanni P, Ferenci P, Colombo M, Fargion S.

Aliment Pharmacol Ther. 2012 Jun;35(12):1434-42. doi: 10.1111/j.1365-2036.2012.05109.x. Epub 2012 Apr 24.

6.

Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.

Aghemo A, Prati GM, Rumi MG, Soffredini R, D'Ambrosio R, Orsi E, De Nicola S, Degasperi E, Grancini V, Colombo M.

Hepatology. 2012 Nov;56(5):1681-7. doi: 10.1002/hep.25867. Epub 2012 Oct 14.

PMID:
22619107
7.

Early virological response in 1220 patients with HCV (genotype lb) chronic hepatitis and cirrhosis treated with PegInterferon plus Ribavirin.

Pascu O, Voiculescu M, Gheorghe L, Micu L, Seicean A, Iliescu L, Mocan T, Ceauşu E, Mateescu B.

Rom J Intern Med. 2011;49(2):105-12.

PMID:
22303601
8.

Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.

Giannini EG, Basso M, Savarino V, Picciotto A.

Aliment Pharmacol Ther. 2010 Feb 15;31(4):502-8. doi: 10.1111/j.1365-2036.2009.04201.x. Epub 2009 Nov 19.

9.

Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.

Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S.

New Microbiol. 2005 Jan;28(1):13-21.

PMID:
15782622
10.

2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines.

European Association of the Study of the Liver.

Liver Int. 2012 Feb;32 Suppl 1:2-8. doi: 10.1111/j.1478-3231.2011.02703.x. Review.

PMID:
22212565
11.

Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.

Namikawa M, Kakizaki S, Yata Y, Yamazaki Y, Horiguchi N, Sato K, Takagi H, Mori M.

J Gastroenterol Hepatol. 2012 Jan;27(1):69-75. doi: 10.1111/j.1440-1746.2011.06802.x.

PMID:
21649727
12.

Viral kinetics during the first weeks of pegylated interferon and ribavirin treatment can identify patients at risk of relapse after its discontinuation: new strategies for such patients?

Milan M, Boninsegna S, Scribano L, Lobello S, Fagiuoli S, Fabris P, Buda A, Martines D.

Infection. 2012 Apr;40(2):173-9. doi: 10.1007/s15010-011-0219-0. Epub 2011 Nov 18.

PMID:
22095532
13.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

14.

Anemia is not predictive of sustained virological response in liver transplant recipients with hepatitis C virus who are treated with pegylated interferon and ribavirin.

Giusto M, Rodriguez M, Navarro L, Rubin A, Aguilera V, San-Juan F, Ortiz C, López-Andujar R, Prieto M, Berenguer M.

Liver Transpl. 2011 Nov;17(11):1318-27. doi: 10.1002/lt.22387.

15.

Treatment of chronic hepatitis C in southern Taiwan.

Chuang WL, Yu ML, Dai CY, Chang WY.

Intervirology. 2006;49(1-2):99-106. Review.

PMID:
16166797
16.

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis.

Kim KH, Jang BK, Chung WJ, Hwang JS, Kweon YO, Tak WY, Lee HJ, Lee CH, Suh JI.

Korean J Hepatol. 2011 Sep;17(3):220-5. doi: 10.3350/kjhep.2011.17.3.220.

17.

Interferon stimulated genes and hepatitis C virus infection.

Asselah T.

J Interferon Cytokine Res. 2012 Dec;32(12):557-62. doi: 10.1089/jir.2012.0059. Epub 2012 Nov 14. Review.

PMID:
23151203
18.

A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), for assessing liver fibrosis.

Toshima T, Shirabe K, Ikegami T, Yoshizumi T, Kuno A, Togayachi A, Gotoh M, Narimatsu H, Korenaga M, Mizokami M, Nishie A, Aishima S, Maehara Y.

J Gastroenterol. 2015 Jan;50(1):76-84. doi: 10.1007/s00535-014-0946-y. Epub 2014 Mar 7.

PMID:
24603981
19.

Effect of maintenance therapy with low-dose peginterferon for recurrent hepatitis C after living donor liver transplantation.

Ueda Y, Marusawa H, Kaido T, Ogura Y, Oike F, Mori A, Ogawa K, Yoshizawa A, Hatano E, Miyagawa-Hayashino A, Haga H, Egawa H, Takada Y, Uemoto S, Chiba T.

J Viral Hepat. 2012 Jan;19(1):32-8. doi: 10.1111/j.1365-2893.2010.01398.x. Epub 2010 Dec 3.

PMID:
21129128
20.

Chronic hepatitis C treatment in näive patients.

Daruich J.

Ann Hepatol. 2010;9 Suppl:65-71.

PMID:
20713999
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk